Lash-Conditioning Ingredients’ Future In Question Ahead Of CIR Review
At an upcoming meeting, a Cosmetic Ingredient Review panel is slated to review safety assessments of two prostaglandin analogues following multiple delays.
HBW Insight - September 29, 2026

The Race To Shake Up The Wet-AMD Market Intensifies
Kodiak Sciences and Ocular Therapeutix are both on track to file for FDA approval with the aim of bringing new treatments to market for age-related macular degeneration.
Scrip - September 29, 2026

Brigham Cardiologist: AI Detection Of Coronary Calcium Could Improve Preventive Care
A randomized trial found AI-informed clinicians initiated or intensified lipid-lowering therapy in 63% of patients at 12 months vs. 19% with standard care. A validation study across 5,468 chest CTs found the Nanox.AI software agreed with expert assessments more than 90% of the time.
Medtech Insight - September 29, 2026

EU Puts AI And EHDS At Center Of Cardiovascular Screening Plan
New proposal from the European Commission will require member states to take a personalized, accessible approach to screening to help meet mortality goals.
Medtech Insight - September 29, 2026

Immix To Target CAR-T Centers In NXC-201 Commercialization Push After Positive Results
The company announced positive Phase II data for the BCMA-directed CAR-T therapy in patients with relapsed/refractory AL amyloidosis.
Scrip - September 29, 2026

DOJ Restores FCA Prosecution Guardrails — But Qui Tam Surge May Blunt The Relief
The DOJ has formally restored False Claims Act prosecution guardrails — but the qui tam filing surge heading toward a third record year may limit the practical relief for medtech and other life sciences companies.
Medtech Insight - September 29, 2026

Reorg Cuts US FDA Chief Counsel Oversight Position At HHS
The Health and Human Services Department eliminated the chief counsel for food, research and drugs, which oversaw legal services for the FDA and NIH.
Medtech Insight - September 29, 2026

AstraZeneca’s $2bn Summit Deal Puts Emerging PD-1/VEGF-ADC Race In Focus
The deal gives AstraZeneca a foothold in the fast-moving PD-1/VEGF field, and the immediate pairing of its ADC sone-ve with ivonescimab in gastric cancer could pave the way to broader combinations for its ADC portfolio.
Scrip - September 29, 2026

Roche’s Pipeline Reset Puts 2027 In Focus As Key Launches, Readouts Loom
The discontinuation of obesity drug emugrobart notwithstanding, Roche is looking to a dense slate of launches and pivotal data ahead. The Swiss major now has to turn a leaner pipeline into a sustained flow of new growth.
Scrip - September 29, 2026

Viatris Challenges Another US Wegovy Patent To Resolve Launch Uncertainty
Mylan is challenging another Wegovy patent after Novo Nordisk declined to sue within the statutory 45-day window after a Paragraph IV challenge, seeking to resolve legal uncertainty surrounding its proposed US generic semaglutide product.
Generics Bulletin - September 29, 2026

Big Win For Prestige Biopharma In Brazil’s Crowded Trastuzumab Biosimilar Market
Even though the trastuzumab biosimilar market is already established in Brazil, the latest Anvisa approval marked an important global expansion milestone for Prestige Biopharma.
Generics Bulletin - September 29, 2026

Novo Expands Into Oral Weekly Obesity Therapy Through Hengrui Deal
Deal Snapshot: By pledging up to $2.6bn in total deal value, Novo is betting on Hengrui’s oral once-weekly GLP-1/GIP receptor agonist for weight loss in an attempt to differentiate from once-weekly injectables with the same dual activating mechanism.
Scrip - September 29, 2026

Breye Secures Cash Boost For Diabetes-Driven Blindness Pill
The Denmark-headquartered firm will progress danegaptide, a first-in-class oral treatment for non-proliferative diabetic retinopathy, into a Phase II trial after raising €67.5m.
Scrip - September 29, 2026

Tanabe IL-33 Antibody Buy Builds Tolerance Pipeline
Tanabe licenses anti-IL-33 antibody globally outside Japan to Tolerance Bio, marking another divestment of one of its clinical candidates following the Bain acquisition.
Scrip - September 29, 2026

How Abu Dhabi Is Racing To Set The Gulf’s Fertility Benchmark With Screening And Diagnosis
Abu Dhabi has set a 2030 roadmap to achieve ambitious global reproductive health ecosystem goals. Prevention and preconception health, genetic screening, fertility diagnosis and treatment and IVF are central elements. L.E.K. Consulting explained how Abu Dhabi is differentiating in its approach.
In Vivo - September 29, 2026

Emugrobart Down In Obesity But Not Out For SMA
Roche completely drops Chugai-originated antibody for obesity and hands all rights back to Japanese firm, which still sees hope in spinal muscular atrophy and may seek alternative licensees.
Scrip - September 29, 2026

Age-Restricted Sales For Weight Loss, Bodybuilding Supplements Coming To California In January
Council for Responsible Nutrition, contesting a similar law in effect in New York since 2024, and Consumer Healthcare Products Association were quick to criticize the California bill after it was signed into law on Sept. 28 by Gov. Gavin Newsom.
HBW Insight - September 29, 2026

TikTok To Brands: Demand More From Creators Or Keep Losing Consumer Trust
TikTok's top brand safety executive tells NAD conference that brands must demand accountability from creators and agencies to reverse advertising's growing trust problem.
HBW Insight - September 29, 2026